[go: up one dir, main page]

SE9801474D0 - Quinoline Derivatives - Google Patents

Quinoline Derivatives

Info

Publication number
SE9801474D0
SE9801474D0 SE9801474A SE9801474A SE9801474D0 SE 9801474 D0 SE9801474 D0 SE 9801474D0 SE 9801474 A SE9801474 A SE 9801474A SE 9801474 A SE9801474 A SE 9801474A SE 9801474 D0 SE9801474 D0 SE 9801474D0
Authority
SE
Sweden
Prior art keywords
propyl
iso
butyl
formula
ethyl
Prior art date
Application number
SE9801474A
Other languages
English (en)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9801474A priority Critical patent/SE9801474D0/sv
Publication of SE9801474D0 publication Critical patent/SE9801474D0/sv
Priority to US09/296,519 priority patent/US6077851A/en
Priority to BRPI9909925-0A priority patent/BR9909925B1/pt
Priority to NZ506641A priority patent/NZ506641A/en
Priority to MEP-2000-612A priority patent/ME00870B/me
Priority to EP99947036A priority patent/EP1073639B1/en
Priority to ES99947036T priority patent/ES2188242T3/es
Priority to JP2000545838A priority patent/JP4045069B2/ja
Priority to HU0102084A priority patent/HU227709B1/hu
Priority to EEP200000613A priority patent/EE04275B1/xx
Priority to OA1200000301A priority patent/OA11547A/en
Priority to DK99947036T priority patent/DK1073639T3/da
Priority to RU2000129672/04A priority patent/RU2197481C2/ru
Priority to CA002329788A priority patent/CA2329788C/en
Priority to PT99947036T priority patent/PT1073639E/pt
Priority to APAP/P/2000/001933A priority patent/AP1293A/en
Priority to CZ20003849A priority patent/CZ297439B6/cs
Priority to IL13816099A priority patent/IL138160A0/xx
Priority to HK01105489.6A priority patent/HK1036618B/en
Priority to CN99805581A priority patent/CN1113057C/zh
Priority to UA2000085078A priority patent/UA60354C2/uk
Priority to PL99343420A priority patent/PL190441B1/pl
Priority to DE69904162T priority patent/DE69904162T2/de
Priority to PCT/SE1999/000676 priority patent/WO1999055678A1/en
Priority to IDW20002183A priority patent/ID26277A/id
Priority to HR20000726A priority patent/HRP20000726B1/xx
Priority to KR1020007011944A priority patent/KR100571534B1/ko
Priority to TR2000/03061T priority patent/TR200003061T2/xx
Priority to YUP-612/00A priority patent/RS50029B/sr
Priority to AU43013/99A priority patent/AU747550B2/en
Priority to AT99947036T priority patent/ATE228505T1/de
Priority to IL138160A priority patent/IL138160A/en
Priority to IS5615A priority patent/IS2082B/is
Priority to ZA200004601A priority patent/ZA200004601B/en
Priority to NO20005254A priority patent/NO315606B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9801474A 1998-04-27 1998-04-27 Quinoline Derivatives SE9801474D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
US09/296,519 US6077851A (en) 1998-04-27 1999-04-22 Quinoline derivatives
AT99947036T ATE228505T1 (de) 1998-04-27 1999-04-26 Chinolinderivate
CZ20003849A CZ297439B6 (cs) 1998-04-27 1999-04-26 Deriváty chinolinu
CN99805581A CN1113057C (zh) 1998-04-27 1999-04-26 喹啉衍生物
MEP-2000-612A ME00870B (me) 1998-04-27 1999-04-26 Derivati hinolina
EP99947036A EP1073639B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
ES99947036T ES2188242T3 (es) 1998-04-27 1999-04-26 Derivados de quinolina.
JP2000545838A JP4045069B2 (ja) 1998-04-27 1999-04-26 キノリン誘導体
HU0102084A HU227709B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
EEP200000613A EE04275B1 (et) 1998-04-27 1999-04-26 Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
OA1200000301A OA11547A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
DK99947036T DK1073639T3 (da) 1998-04-27 1999-04-26 Chinolinderivater
RU2000129672/04A RU2197481C2 (ru) 1998-04-27 1999-04-26 Производные хинолина
CA002329788A CA2329788C (en) 1998-04-27 1999-04-26 Quinoline derivatives
PT99947036T PT1073639E (pt) 1998-04-27 1999-04-26 Derivados de quinolina
APAP/P/2000/001933A AP1293A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
BRPI9909925-0A BR9909925B1 (pt) 1998-04-27 1999-04-26 derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
IL13816099A IL138160A0 (en) 1998-04-27 1999-04-26 Quinoline derivatives
HK01105489.6A HK1036618B (en) 1998-04-27 1999-04-26 Quinoline derivatives
NZ506641A NZ506641A (en) 1998-04-27 1999-04-26 Quinoline derivatives useful in the treatment of autoimmune disorders
UA2000085078A UA60354C2 (uk) 1998-04-27 1999-04-26 Похідні хіноліну, спосіб їх одержання (варіанти) та спосіб лікування ссавців
PL99343420A PL190441B1 (pl) 1998-04-27 1999-04-26 Nowe pochodne 1-metylo-2-okso-chinolino-3-karboksyamidu zawierające je kompozycje farmaceutyczne oraz sposób ich wytwarzania
DE69904162T DE69904162T2 (de) 1998-04-27 1999-04-26 Chinolinderivate
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
IDW20002183A ID26277A (id) 1998-04-27 1999-04-26 Turunan-turunan kuinolina
HR20000726A HRP20000726B1 (hr) 1998-04-27 1999-04-26 Derivati kinolina
KR1020007011944A KR100571534B1 (ko) 1998-04-27 1999-04-26 퀴놀린 유도체
TR2000/03061T TR200003061T2 (tr) 1998-04-27 1999-04-26 Kinolin türevleri
YUP-612/00A RS50029B (sr) 1998-04-27 1999-04-26 Derivati hinolina
AU43013/99A AU747550B2 (en) 1998-04-27 1999-04-26 Quinoline derivatives
IL138160A IL138160A (en) 1998-04-27 2000-08-30 Quinoline derivatives
IS5615A IS2082B (is) 1998-04-27 2000-08-31 Kvínólínafleiður
ZA200004601A ZA200004601B (en) 1998-04-27 2000-09-01 Quinoline derivatives.
NO20005254A NO315606B1 (no) 1998-04-27 2000-10-19 Kinolinderivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Publications (1)

Publication Number Publication Date
SE9801474D0 true SE9801474D0 (sv) 1998-04-27

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Country Status (32)

Country Link
EP (1) EP1073639B1 (sv)
JP (1) JP4045069B2 (sv)
KR (1) KR100571534B1 (sv)
CN (1) CN1113057C (sv)
AP (1) AP1293A (sv)
AT (1) ATE228505T1 (sv)
AU (1) AU747550B2 (sv)
BR (1) BR9909925B1 (sv)
CA (1) CA2329788C (sv)
CZ (1) CZ297439B6 (sv)
DE (1) DE69904162T2 (sv)
DK (1) DK1073639T3 (sv)
EE (1) EE04275B1 (sv)
ES (1) ES2188242T3 (sv)
HR (1) HRP20000726B1 (sv)
HU (1) HU227709B1 (sv)
ID (1) ID26277A (sv)
IL (2) IL138160A0 (sv)
IS (1) IS2082B (sv)
ME (1) ME00870B (sv)
NO (1) NO315606B1 (sv)
NZ (1) NZ506641A (sv)
OA (1) OA11547A (sv)
PL (1) PL190441B1 (sv)
PT (1) PT1073639E (sv)
RS (1) RS50029B (sv)
RU (1) RU2197481C2 (sv)
SE (1) SE9801474D0 (sv)
TR (1) TR200003061T2 (sv)
UA (1) UA60354C2 (sv)
WO (1) WO1999055678A1 (sv)
ZA (1) ZA200004601B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
MX2007007599A (es) 2004-12-21 2007-12-07 Serono Lab Dervivados ciclicos de sulfonilamino y uso de los mismos.
EA014238B1 (ru) 2005-01-31 2010-10-29 Мерк Сероно Са Производные n-гидроксиамида и их применение
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
ME02414B (me) 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
EP2542080B1 (en) * 2010-03-03 2016-08-31 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
CA2791709A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
JP5881691B2 (ja) 2010-07-09 2016-03-09 アクティブ バイオテック エイビー キノリン−３−カルボキサミドの製造方法
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
JP5934202B2 (ja) * 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
HK1199820A1 (en) 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) * 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
US20140235670A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries, Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
EP3041472B1 (en) 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
JP6715833B2 (ja) 2014-11-19 2020-07-01 アクティブ バイオテック エイビー 白血病の治療に使用するためのキノリンカルボキサミド
IL293469B2 (en) 2019-12-19 2024-04-01 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation
US20230085883A1 (en) 2020-03-03 2023-03-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
BR112022023448A2 (pt) * 2020-05-21 2023-01-31 Stemsynergy Therapeutics Inc Inibidores de notch e usos dos mesmos
WO2022018240A1 (en) 2020-07-23 2022-01-27 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
CN117295492A (zh) 2021-05-25 2023-12-26 活跃生物技术有限公司 多个他喹莫德粒子及其用途
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
WO2023122612A2 (en) * 2021-12-20 2023-06-29 The Johns Hopkins University Compounds for treatment of cancer
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SU1735288A1 (ru) * 1990-03-05 1992-05-23 Харьковский государственный фармацевтический институт Способ получени N-R-замещенных амидов 4-гидроксихинолон-2 карбоновой -3-кислоты
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds

Also Published As

Publication number Publication date
ME00870B (me) 2008-11-28
UA60354C2 (uk) 2003-10-15
AP1293A (en) 2004-08-30
PL343420A1 (en) 2001-08-13
EP1073639A1 (en) 2001-02-07
EE200000613A (et) 2002-04-15
CA2329788A1 (en) 1999-11-04
KR100571534B1 (ko) 2006-04-14
EP1073639B1 (en) 2002-11-27
IL138160A (en) 2006-04-10
JP2002513006A (ja) 2002-05-08
OA11547A (en) 2004-05-24
ZA200004601B (en) 2002-02-27
AP2000001933A0 (en) 2000-12-31
EE04275B1 (et) 2004-04-15
HU227709B1 (en) 2011-12-28
AU4301399A (en) 1999-11-16
DE69904162D1 (de) 2003-01-09
CZ20003849A3 (cs) 2001-03-14
CN1298393A (zh) 2001-06-06
HRP20000726B1 (hr) 2009-04-30
BR9909925B1 (pt) 2010-09-21
HRP20000726A2 (en) 2001-04-30
NO20005254L (no) 2000-12-27
ATE228505T1 (de) 2002-12-15
PT1073639E (pt) 2003-04-30
ID26277A (id) 2000-12-14
JP4045069B2 (ja) 2008-02-13
RU2197481C2 (ru) 2003-01-27
HUP0102084A2 (hu) 2001-11-28
DK1073639T3 (da) 2003-03-24
IL138160A0 (en) 2001-10-31
NO315606B1 (no) 2003-09-29
NZ506641A (en) 2002-03-28
HK1036618A1 (en) 2002-01-11
ES2188242T3 (es) 2003-06-16
YU61200A (sh) 2003-07-07
HUP0102084A3 (en) 2002-12-28
NO20005254D0 (no) 2000-10-19
IS2082B (is) 2006-02-15
BR9909925A (pt) 2001-01-09
PL190441B1 (pl) 2005-12-30
CN1113057C (zh) 2003-07-02
CA2329788C (en) 2004-11-23
DE69904162T2 (de) 2003-08-21
CZ297439B6 (cs) 2006-12-13
RS50029B (sr) 2008-11-28
IS5615A (is) 2000-08-31
WO1999055678A1 (en) 1999-11-04
TR200003061T2 (tr) 2001-01-22
AU747550B2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
SE9801474D0 (sv) Quinoline Derivatives
SE9802549D0 (sv) Quinoline derivatives
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
AP1425A (en) Quinoline derivatives.
ATE37179T1 (de) Dihydropyridazinone.
EE200100513A (et) Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
FI970246A7 (sv) Dihydrobensofuraner
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
FI810389L (fi) Foerfarande foer framstaellning av substituerade imidazolderivat
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
FI955085A0 (sv) Nya diosmetinföreningar, förfarande för deras framställning och farmaceutiska kompositioner som innehåller dessa föreningar
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
EA200101050A1 (ru) Замещенные бензолактамные соединения
IE832466L (en) Indoles and intermediates.
SE0400440D0 (sv) Novel Cinnamic Amides
SE0401578D0 (sv) Novel compounds
DE60009932D1 (de) 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole
FI834789A0 (fi) Foerfarande foer framstaellning av 1,1-difenylpropanolderivat
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem
SE9902147D0 (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
FI870098A0 (fi) Nya pregnanderivat, foerfaranden foer deras framstaellning och farmaceutiska preparat, vilka innehaoller desamma.